bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 and Supplementary Figures 1 through 3 from Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
Authors: Ishibashi Mariko , Tamura Hideto , Sunakawa Mika , Kondo-Onodera Asaka , Okuyama Namiko , Hamada Yasuko , Moriya Keiichi , Choi Inhak , Tamada Koji , Inokuchi Koiti
Published: April 2023

Supplementary Table S1 Primer Sequence. Supplementary Figure S1. (A) Surface antigen expression and (B) Cell morphology of MOSTI-1 cells, and (C) drug sensitivity to melphalan and bortezomib of MOSTI-1, U266, and RPMI8226 cells. Supplementary Figure S2. Expression of cell cycle-related and antiapoptotic genes in B7-H1.KMS28-PE (B7-H1) and mock.KMS28-PE (mock) cells. Supplementary Figure S3. No effect of cell aggregation on drug sensitivity in MOSTI-1.
Supplementary Table 1, Figures 1 - 3 from Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy
Authors: Ochi Toshiki , Nakatsugawa Munehide , Chamoto Kenji , Tanaka Shinya , Yamashita Yuki , Guo Tingxi , Fujiwara Hiroshi , Yasukawa Masaki , Butler Marcus O. , Hirano Naoto
Published: April 2023

Supplementary table S1. Amino acid sequences of A24/WT1235-related peptides. Supplementary figure S1. The TAK1β hemi-chain has a dominant role in dictating A24/WT1235 reactivity. Supplementary figure S2. All forty-five Jurkat 76/CD8 TCR transfectants express similar levels of CD3/TCR complexes. Supplementary figure S3. Jurkat 76/CD8 TCR transfectants show different degrees of A24/WT1235 tetramer positivity.
Supplementary Movie S3 from Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells
Authors: Zahm Christopher D. , Colluru Viswa T. , McNeel Douglas G.
Published: April 2023

Representative video of OT-1 T cells interacting with SIINFEKL (OVA) loaded APC.
Supplementary Movie S1 from Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells
Authors: Zahm Christopher D. , Colluru Viswa T. , McNeel Douglas G.
Published: April 2023

Representative video of OT-1 T cells interacting with control loaded APC.
Figure S2 from IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
Authors: Dubois Sigrid , Conlon Kevin C. , Müller Jürgen R. , Hsu-Albert Jennifer , Beltran Nancy , Bryant Bonita R. , Waldmann Thomas A.
Published: April 2023

Representation of surface marker analyses on gated NK cells with constant expressions before and after IL-15 infusions.
Supplementary Figures 1 - 3 from Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy
Authors: Schrand Brett , Berezhnoy Alexey , Brenneman Randall , Williams Anthony , Levay Agata , Kong Ling-Yuan , Rao Ganesh , Zhou Shouhao , Heimberger Amy B. , Gilboa Eli
Published: April 2023

PDF file - 87K, Supplementary Figure 1. Sequence and secondary structure ofVEGF-4-1BB and OPN-4-1BB aptamer conjugates. Supplementary Figure 2. Biodistribution of VEGF-4-1BB aptamer conjugates. Supplementary Figure 3. OPN-targeted costimulation inhibits tumor growth.
Supplementary Figure 3 from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Authors: Hudecek Michael , Sommermeyer Daniel , Kosasih Paula L. , Silva-Benedict Anne , Liu Lingfeng , Rader Christoph , Jensen Michael C. , Riddell Stanley R.
Published: April 2023

10 million (A) CD8+ TCM-derived CD19-CAR-T-cells, (B) CD19-CAR-T-cells derived from an unselected T-cell population, or (C) CD8+ TCM-derived ROR1-CAR-T-cells were injected into tumor-free NSG mice. After 24 hours, bone marrow, spleens, and peripheral blood were isolated and analyzed for the presence of T-cells (CD45+/CD4+ or CD45+/CD8+) and the expression of activation markers CD25 and CD69 by flow cytometry.
Supplementary Table 1 from Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Authors: Wang Qiong J. , Yu Zhiya , Griffith Kayla , Hanada Ken-ichi , Restifo Nicholas P. , Yang James C.
Published: April 2023

Supplementary Table 1: Predicted HLA-binding affinity of mutated KRAS G12D and KRAS G12V.
Supplementary Figure 1 from Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Authors: Wang Qiong J. , Yu Zhiya , Griffith Kayla , Hanada Ken-ichi , Restifo Nicholas P. , Yang James C.
Published: April 2023

(A) mTCR Expression of human PBL co-transduced with oligoclonal TCR alpha and beta chains. (B) Reactivity of PBL co-transduced with oligoclonal TCR alpha and beta chains. (C) Correlation between KRAS G12D expression and reactivity of KRAS G12D-reactive TCR.
Supplementary Figures 1 through 7 from T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Authors: Zah Eugenia , Lin Meng-Yin , Silva-Benedict Anne , Jensen Michael C. , Chen Yvonne Y.
Published: April 2023

Fig. S1: CD20 CAR T cells with a long extracellular spacer demonstrate superior in vitro functionality. Fig. S2: CD19-OR-CD20 CARs are efficiently expressed on the surface of primary human T cells. Fig. S3: CRISPR/Cas9-edited Raji cells do not express CD19. Fig. S4: Improved CD20 targeting does not compromise CD19 detection by OR-gate CARs. Fig. S5: OR-gate CAR-T cells do not become exhausted earlier or more severely compared to single-input CD20 CAR-T cells.Fig. S6: T cells expressing OR-gate CARs, but not single-input CD19 CARs, can efficiently target both WT and CD19- mutant Raji tumors in vivo. Fig. S7: Raji cells retain antigen expression in vivo.
Supplemental Table 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Cloning primers.
Supplemental Table 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Feline mammary carcinoma patients.
Supplemental Figure 6 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Specificity control of feline immune serum.
Supplemental Figure 4 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
Authors: Künkele Annette , Johnson Adam J. , Rolczynski Lisa S. , Chang Cindy A. , Hoglund Virginia , Kelly-Spratt Karen S. , Jensen Michael C.
Published: April 2023

Supplemental Fig. 4. Expression of Fas and FasL after siRNA knockdown.
Supplemental Figure 5 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Specificity control of mouse immune serum.
Supplemental Figure 2 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
Authors: Künkele Annette , Johnson Adam J. , Rolczynski Lisa S. , Chang Cindy A. , Hoglund Virginia , Kelly-Spratt Karen S. , Jensen Michael C.
Published: April 2023

Supplemental Fig.2. Similar CD171 expression levels by xenografted NB cell lines and patient NB specimens.
Supplemental Figure 1 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
Authors: Künkele Annette , Johnson Adam J. , Rolczynski Lisa S. , Chang Cindy A. , Hoglund Virginia , Kelly-Spratt Karen S. , Jensen Michael C.
Published: April 2023

Supplemental Fig.1. Phenotypic similarity between isolated CD45RO+CD62L+ human TCM expanded following lentiviral transduction with spacer variant 2G-CARs.
Supplemental Figure 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Authors: Gibson Heather M. , Veenstra Jesse J. , Jones Richard , Vaishampayan Ulka , Sauerbrey Michele , Bepler Gerold , Lum Lawrence , Reyes Joyce , Weise Amy , Wei Wei-Zen
Published: April 2023

Authentication of the cat mammary tumor lines K248 and K12 used in this study via short tandem repeat (STR) analysis at 4 loci.
Supplementary Tables 1 through 3, Supplementary Figure Legends, and Supplementary Materials and Methods from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

Supplementary Table S1. Similarity between CD47 variants across species. Supplementary Table S2. Similarity between SIRPα variants across species. Supplementary Table S3. Summary of tumor necrosis scores following treatment with the indicated therapies. Supplementary Figure Legends. Supplementary Materials and Methods.
Supplementary Figure S7 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

Combination therapy with CD47-blockade and anti-CD20 antibodies produces in vivo efficacy with no overt toxicity.
Supplementary Figure S4 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

Canine macrophages respond to CD47-blocking therapies in vitro.
Supplementary Figure S1 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Authors: Zigler Maya , Shir Alexei , Joubran Salim , Sagalov Anna , Klein Shoshana , Edinger Nufar , Lau Jeffrey , Yu Shang-Fan , Mizraji Gabriel , Globerson Levin Anat , Sliwkowski Mark X. , Levitzki Alexander
Published: April 2023

Supplementary Figure illustrating the expression of TLR3 in cell line that deferentially express HER2
Supplementary Tables 1 - 5, Figures 1 - 10 from Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
Authors: Hansmann Leo , Blum Lisa , Ju Chia-Hsin , Liedtke Michaela , Robinson William H. , Davis Mark M.
Published: April 2023

Supplementary Table 1: Supplementary subject data. Supplementary Table 2: CyFACS buffer and cell culture medium recipes. Supplementary Table 3: Antibodies used for CyTOF staining. Supplementary Table 4: Antibodies/Reagents used for FACS staining. Supplementary Table 5: Two-dimensional CyTOF gates. Supplementary Figure 1: Typical two-dimensional identification of PBMC subpopulations. Supplementary Figure 2: Heterogeneity of immune phenotypes in MM, AM, and MGUS patients. Supplementary Figure 3: Cell frequency differences between MM, MGUS/AM, and healthy control PBMC populations. Supplementary figure 4: Phenotypic characterization of CD24loCD38+CD27+ B cells in MM samples. Supplementary Figure 5: CD24loCD38+CD27+ B cells do not show characteristics of malignant plasma cell differentiation. Supplementary Figure 6: Citrus analysis for the comparison of PBMC clusters of MM patients and healthy controls. Supplementary Figure 7: Mass cytometry and FACS side by side comparison of CD24loCD38+CD27+ B cell populations in MM samples. Supplementary Figure 8: FISH analysis for t(11;14) in B cell subsets of subject 10 with a t(11;14) positive MM clone. Supplementary Figure 9: Validation of phosphorylation responses in two additional MM and healthy control samples. Supplementary Figure 10: CD24loCD38+CD27+ B cells in the peripheral blood of colorectal cancer patients.
Supplementary Figure 7 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 234K, Fig. S7. Tim-3 blockade improves NK cell function.
Supplementary Figure 5 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 81K, Fig. S5. Tim-3 engagement on NK cells from healthy donors inhibits their cytotoxicity.
Supplementary Figure 3 from PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Authors: MacFarlane Alexander W. , Jillab Mowafaq , Plimack Elizabeth R. , Hudes Gary R. , Uzzo Robert G. , Litwin Samuel , Dulaimi Essel , Al-Saleem Tahseen , Campbell Kerry S.
Published: April 2023

PDF file - 471K, Correlation between PD-1 expression and CD69 expression on T cells in pre-operative blood samples. Correlation of PD-1 expression on T cells (x-axis) to CD69 expression T cells (y-axis) is shown. A vertical line marks the median PD-1 expression on and the median CD69 expression is marked by a horizontal line. Statistical significance was calculated by a Spearman correlation. A least squares linear fit is shown as a thick black line.
Supplementary Figure 2 from PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Authors: MacFarlane Alexander W. , Jillab Mowafaq , Plimack Elizabeth R. , Hudes Gary R. , Uzzo Robert G. , Litwin Samuel , Dulaimi Essel , Al-Saleem Tahseen , Campbell Kerry S.
Published: April 2023

PDF file - 5296K, Lymphocyte gating strategy. A. Leukocytes were gated as described in Supplemental Figure 1. B. T Cells were identified as CD3+ lymphocytes and NK cells as (CD3- CD56+) lymphocytes. C. T cells were sub-divided by CD4 and CD8 expression. D. CD8+ T cells were divided into subsets of Naive (CD45RA+ CD62L+), Effector (CD45RA+ CD62L-), Central Memory (CD45RA- CD62L+), and Effector Memory (CD45RA- CD62L-). E. CD4+ T Cells were sub-divided as for CD8+ T cells. F. B cells were identified as CD19+ lymphocytes. G. NK Cells were further divided into CD56bright and CD56dim phenotypes. H. B Cells were sub-divided into Naive (CD20+ CD27-), Memory (CD20+ CD27+), and plasmacytoid (CD20- CD27+). Fully differentiated plasma cells fall outside these gates because they are CD45-.
Supplementary Figure 2 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 93K, Fig. S2. NK cells from melanoma patients down-regulate the expression of cytokine receptors, rendering them refractory to cytokine stimulation.
Supplemental Tables 1 and 2 from Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
Authors: Sridharan Vishwajith , Gjini Evisa , Liao Xiaoyun , Chau Nicole G. , Haddad Robert I. , Severgnini Mariano , Hammerman Peter , El-Naggar Adel , Freeman Gordon J. , Hodi F. Stephen , Rodig Scott J. , Dranoff Glenn , Schoenfeld Jonathan D.
Published: April 2023

Genes associated with poor immune infiltration and seromic profiles
Supplementary Figure Legends t from PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors
Authors: Haro Marcela A. , Littrell Chad A. , Yin Zhaojun , Huang Xuefei , Haas Karen M.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 1 from CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma
Authors: Chao Timothy , Furth Emma E. , Vonderheide Robert H.
Published: April 2023

Increased total number of TANs with progressive 4662 tumor growth.
Supplementary Figure 1 from PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors
Authors: Haro Marcela A. , Littrell Chad A. , Yin Zhaojun , Huang Xuefei , Haas Karen M.
Published: April 2023

Figure S1. Phenotype of dBSM- and Tn-specific B cells
Supplementary Material 1 - 4 from The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
Authors: Hemmerle Teresa , Neri Dario
Published: April 2023

PDF file - 160K, SUPPLEMENTARY MATERIAL 1. F8-IFNg. SUPPLEMENTARY MATERIAL 2. Statistical analysis of targeting and therapy data using GraphPad PRISM. SUPPLEMENTARY MATERIAL 3. Assessment of toxicity by observation of changes in body weight of treated mice with F8-IFNg, KSF-IFNg or PBS. SUPPLEMENTARY MATERIAL 4. Assessment of toxicity by observation of changes in body weight of treated mice in the combination therapies in Lewis lung carcinoma bearing C57BL/6 mice.
Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Authors: Quetglas José I. , Labiano Sara , Aznar M. Ángela , Bolaños Elixabet , Azpilikueta Arantza , Rodriguez Inmaculada , Casales Erkuden , Sánchez-Paulete Alfonso R. , Segura Víctor , Smerdou Cristian , Melero Ignacio
Published: April 2023

Supplementary figure 1. Similar survival results with anti-PD-1 or anti-PD-L1 in the combination with SFV-IL12 for B16-OVA-derived tumors.
Supplemental figure 5: from Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
Authors: Joseph Ann Mary , Srivastava Ratika , Zabaleta Jovanny , Davila Eduardo
Published: April 2023

Model depicting signaling interaction between T cell receptor, TLR2 and 4-1BB in CD8+ T cells.
Supplementary Figure 7 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Post-sepsis led to extra medullary proliferation of TAM through CXCR4/CXCL12 signaling
Supplementary Figure 5 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Expression of genes related to M1 and M2 polarization in TAM derived from naïve or post-sepsis mice.
Supplementary Movie 5 from Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
Authors: Liadi Ivan , Singh Harjeet , Romain Gabrielle , Rey-Villamizar Nicolas , Merouane Amine , Adolacion Jay R T. , Kebriaei Partow , Huls Helen , Qiu Peng , Roysam Badrinath , Cooper Laurence J.N. , Varadarajan Navin
Published: April 2023

Movie M5. Representative example of a CAR4 cell that kills multiple tumor cells.
Supplementary Movie 4 from Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
Authors: Liadi Ivan , Singh Harjeet , Romain Gabrielle , Rey-Villamizar Nicolas , Merouane Amine , Adolacion Jay R T. , Kebriaei Partow , Huls Helen , Qiu Peng , Roysam Badrinath , Cooper Laurence J.N. , Varadarajan Navin
Published: April 2023

Movie M4. Representative example of a CAR8 cell that kills multiple tumor cells.
Supplementary Movie 3 from Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
Authors: Liadi Ivan , Singh Harjeet , Romain Gabrielle , Rey-Villamizar Nicolas , Merouane Amine , Adolacion Jay R T. , Kebriaei Partow , Huls Helen , Qiu Peng , Roysam Badrinath , Cooper Laurence J.N. , Varadarajan Navin
Published: April 2023

Movie M3. Representative example of a CAR8 cell from the S3 subgroup.
Table S1 from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Antibodies used in this study
Supplementary Figure 4 from Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Authors: Homet Moreno Blanca , Zaretsky Jesse M. , Garcia-Diaz Angel , Tsoi Jennifer , Parisi Giulia , Robert Lidia , Meeth Katrina , Ndoye Abibatou , Bosenberg Marcus , Weeraratna Ashani T. , Graeber Thomas G. , Comin-Anduix Begoña , Hu-Lieskovan Siwen , Ribas Antoni
Published: April 2023

Gating strategy of CD11c+B220-, CD11c+B220+, CD11c+B220-CD8+ and CD11c+B220-CD103+ cells; gating strategy of CD11b+MHC-IIhigh DCs in CD11c+ cells; gating strategy of CD11b+F4/80+TAMs, CD11b+F4/80+MHC-IIlow TAMs and CD11b+F4/80+MHC-IIhigh TAMs; gating strategy of MO-MDSC (CD11b+Ly6ChighLy6Glow) and PMN-MDSC (CD11b+Ly6ClowLy6Ghigh); gating strategy of Tregs (CD4+CD25+FoxP3+); corresponding normalized enrichment scores (NES), P values and false discovery rates (FDR) of the GSEA plots for YUMM2.1 versus YUMM1.1 enriched pathways involved in immune response, cytokine production and inflammatory response.
Supplementary Figure 3 from Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Authors: Homet Moreno Blanca , Zaretsky Jesse M. , Garcia-Diaz Angel , Tsoi Jennifer , Parisi Giulia , Robert Lidia , Meeth Katrina , Ndoye Abibatou , Bosenberg Marcus , Weeraratna Ashani T. , Graeber Thomas G. , Comin-Anduix Begoña , Hu-Lieskovan Siwen , Ribas Antoni
Published: April 2023

IGV plot of RNA-Seq from YUMM1.1, YUMM1.7 and YUMM2.1; western blot analysis of cytoplasmic and nuclear beta-catenin in YUMM1.7 and YUMM2.1 cell lines with or without exposure to 10 uM 4HT for 48 hours; top-flash activity of total beta-catenin in YUMM1.7 and YUMM2.1 with or without exposure to 10uM 4HT for 48 hours; representative immunofluorescence of beta-catenin stained non-treated tumors.
Supplemental Figure 1 from Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
Authors: Liu Scot D. , Chalouni Cecile , Young Judy C. , Junttila Teemu T. , Sliwkowski Mark X. , Lowe John B.
Published: April 2023

NK cells with high affinity FcgRIIIa also exhibit more protein tyrosine phosphorylation in response to afucosylated antibodies compared to fucosylated ones.
Supplementary Methods from Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules
Authors: Schmittnaegel Martina , Levitsky Victor , Hoffmann Eike , Georges Guy , Mundigl Olaf , Klein Christian , Knoetgen Hendrik
Published: April 2023

Protein Purification, Flow cytometry, Time lapse live cell imaging by confocal microscopy, Stimulation of PBMCs with homo-and heterodimeric CMV-pMHCI-IgGs, Pharmacokinetic measurement.
Supplementary Figure 4 from Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
Authors: Vandeveer Amanda J. , Fallon Jonathan K. , Tighe Robert , Sabzevari Helen , Schlom Jeffrey , Greiner John W.
Published: April 2023

Immunohistochemical detection of CD4 and CD8 immune cell subsets in the bladders of mice treated with Avelumab, BCG or Avelumab plus BCG
Supplementary Movie 4 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Movie 4. Serial killing of tumor targets by CAR.OT-I effector cells following engagement through the TCR
Supplementary Table 1 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Authors: Kitano Shigehisa , Postow Michael A. , Ziegler Carly G.K. , Kuk Deborah , Panageas Katherine S. , Cortez Czrina , Rasalan Teresa , Adamow Mathew , Yuan Jianda , Wong Philip , Altan-Bonnet Gregoire , Wolchok Jedd D. , Lesokhin Alexander M.
Published: April 2023

PDF file - 103K, Supplemental table 1. Univariate analysis of relationship between m-MDSC and overall survival at pre-treatment baseline and week 6 after ipilimumab treatment at 10mg/kg and 3mg/kg.
Supplementary Figure 2 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Supplementary Figure 2. OVA257 peptide dose does not affect effector cell maturation status.
Supplementary Figure 3 from Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells
Authors: Matsuzaki Junko , Tsuji Takemasa , Luescher Immanuel , Old Lloyd J. , Shrikant Protul , Gnjatic Sacha , Odunsi Kunle
Published: April 2023

PDF file - 152K, MHC class II antigen presentation pathway of intracellular NY-ESO-1 by SK-MEL-37.
Supplementary Figure 1 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Authors: Kitano Shigehisa , Postow Michael A. , Ziegler Carly G.K. , Kuk Deborah , Panageas Katherine S. , Cortez Czrina , Rasalan Teresa , Adamow Mathew , Yuan Jianda , Wong Philip , Altan-Bonnet Gregoire , Wolchok Jedd D. , Lesokhin Alexander M.
Published: April 2023

PDF file - 142K, Supplemental Figure 1. m-MDSC gating strategy using various HLA-DR cutoffs based on expression of HLA-DR in lineage positive cells yields differing m-MDSC frequencies and is susceptible to inter-user variability.
Supplementary Figure 2 from Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells
Authors: Matsuzaki Junko , Tsuji Takemasa , Luescher Immanuel , Old Lloyd J. , Shrikant Protul , Gnjatic Sacha , Odunsi Kunle
Published: April 2023

PDF file - 97K, Effect of IFN-gamma treatment of HLA-DP4+ melanoma cell lines on intracellular NY-ESO-1 to TR-CD4.
Supplementary Figure 1 from Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells
Authors: Matsuzaki Junko , Tsuji Takemasa , Luescher Immanuel , Old Lloyd J. , Shrikant Protul , Gnjatic Sacha , Odunsi Kunle
Published: April 2023

PDF file - 110K, Cell surface molecules expressed on SK-MEL-37.
Supplemental Table 1 from MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Authors: Yaddanapudi Kavitha , Rendon Beatriz E. , Lamont Gwyneth , Kim Eun Jung , Al Rayyan Numan , Richie Jamaal , Albeituni Sabrin , Waigel Sabine , Wise Ashley , Mitchell Robert A.
Published: April 2023

Supplemental Table 1. List of human antibodies used for flow cytometry.
Supplemental Figure Legends and Methods from MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation
Authors: Yaddanapudi Kavitha , Rendon Beatriz E. , Lamont Gwyneth , Kim Eun Jung , Al Rayyan Numan , Richie Jamaal , Albeituni Sabrin , Waigel Sabine , Wise Ashley , Mitchell Robert A.
Published: April 2023

Supplemental Figure Legends and Methods
Supplementary Figure 1 from T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Authors: Dennis Kristen L. , Saadalla Abdulrahman , Blatner Nichole R. , Wang Shuya , Venkateswaran Vysak , Gounari Fotini , Cheroutre Hilde , Weaver Casey T. , Roers Axel , Egilmez Nejat K. , Khazaie Khashayarsha
Published: April 2023

Representative analysis of bone marrow reconstitution efficiency. (A) FACS of total live MNC derived from the intestine of donor CD45.2+ mouse. (B) Frequencies of CD45.1+ and CD45.2+ cells in the intestine of a representative chimeric mouse. CD45.1 donor bone marrow cells were depleted of Lin+ cells and injected into retro-orbital sinus of lethally irradiated 2 month old CD45.2 APCdelta468 mice. To establish the level of bone marrow reconstitution, chimeric APCdelta468 mice were aged to 4 months of age and intestinal MNC were isolated and analyzed by flow cytometry for expression of CD45.2 and CD45.1.
Supplementary Materials and Methods from IL17A-Mediated Endothelial Breach Promotes Metastasis Formation
Authors: Kulig Paulina , Burkhard Sara , Mikita-Geoffroy Joanna , Croxford Andrew L. , Hövelmeyer Nadine , Gyülvészi Gabor , Gorzelanny Christian , Waisman Ari , Borsig Lubor , Becher Burkhard
Published: April 2023

Supplementary Materials and Methods
Supplementary Table S4 from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Authors: Johnson Douglas B. , Lovly Christine M. , Flavin Marisa , Panageas Katherine S. , Ayers Gregory D. , Zhao Zhiguo , Iams Wade T. , Colgan Marta , DeNoble Sarah , Terry Charles R. , Berry Elizabeth G. , Iafrate A. John , Sullivan Ryan J. , Carvajal Richard D. , Sosman Jeffrey A.
Published: April 2023

Clinical and molecular characteristics of PD-L1 staining cohort.
Supplementary Table S3 from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Authors: Johnson Douglas B. , Lovly Christine M. , Flavin Marisa , Panageas Katherine S. , Ayers Gregory D. , Zhao Zhiguo , Iams Wade T. , Colgan Marta , DeNoble Sarah , Terry Charles R. , Berry Elizabeth G. , Iafrate A. John , Sullivan Ryan J. , Carvajal Richard D. , Sosman Jeffrey A.
Published: April 2023

Genes assessed at MGH by SNaPshot Testing1.
Supplementary Tables 1 and Figures 1 - 9 from Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma
Authors: Saito Yoichi , Ohnishi Koji , Miyashita Azusa , Nakahara Satoshi , Fujiwara Yukio , Horlad Hasita , Motoshima Takanobu , Fukushima Satoshi , Jinnin Masatoshi , Ihn Hironobu , Takeya Motohiro , Komohara Yoshihiro
Published: April 2023

Table S1. Additional univariate (A) and multivariate (B) Cox regression analyses of potential prognostic factors for overall survival. Figure S1. Decolorized sections. Immunostaining of the negative control melanomas and RLNs treated with or without melanin bleaching. Figure S2. Hematoxylin-eosin staining of the sinus areas in the RLNs. The lower images are magnifications of the squares in the upper images. Arrows indicate RLN sinus areas. Figure S3. Immunohistochemical analysis of CD169+, CD68+ and CD163+ macrophages in the RLNs. Higher magnification images of Figure 1B. Figure S4. The expression of CD14 in the sinus macrophages in the RLNs. An immunostaining of CD14 in the RLNs. Figure S5. Overall Kaplan-Meier survival curves for the 84 melanoma patients as related to the clinicopathological features. Figure S6. The expression of TIA-1 in infiltrating CD8+ T cells in the melanomas. An immunostaining of TIA-1 in the melanomas. The lower image is a magnified view of the square in the upper image. Figure S7. The expression of granzyme B in infiltrating CD8+ T cells in the melanomas. An immunostaining of Granzyme B in the melanomas. The lower image is a magnified view of the square in the upper image. Figure S8. The expression of CD43, the major ligand for CD169, in the sinus macrophages in the RLNs. An immunostaining of CD43 in the RLNs. The lower image is a magnified view of the square in the upper image. Figure S9. Flow cytometry of CD169 and costimulatory molecules on day 3 in macrophages cultured with or without IFN-alpha stimulation during the last 24 hours of culture. One representative result (of three) is shown. The black dashed lines in the histograms represent isotype controls.
Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Authors: Roemer Margaretha G.M. , Advani Ranjana H. , Redd Robert A. , Pinkus Geraldine S. , Natkunam Yasodha , Ligon Azra H. , Connelly Courtney F. , Pak Christine J. , Carey Christopher D. , Daadi Sarah E. , Chapuy Bjoern , de Jong Daphne , Hoppe Richard T. , Neuberg Donna S. , Shipp Margaret A. , Rodig Scott J.
Published: April 2023

Percent exact agreement and weighted Cohen's kappa coefficient with bootstrap 95% confidence intervals.
Supplementary Data from Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
Authors: Trotta Anna Maria , Ottaiano Alessandro , Romano Carmela , Nasti Guglielmo , Nappi Anna , De Divitiis Chiara , Napolitano Maria , Zanotta Serena , Casaretti Rossana , D'Alterio Crescenzo , Avallone Antonio , Califano Daniela , Iaffaioli Rosario Vincenzo , Scala Stefania
Published: April 2023

Figure Legends
Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Authors: Rhode Peter R. , Egan Jack O. , Xu Wenxin , Hong Hao , Webb Gabriela M. , Chen Xiaoyue , Liu Bai , Zhu Xiaoyun , Wen Jinghai , You Lijing , Kong Lin , Edwards Ana C. , Han Kaiping , Shi Sixiang , Alter Sarah , Sacha Jonah B. , Jeng Emily K. , Cai Weibo , Wong Hing C.
Published: April 2023

Supplementary methods. Supplementary Table S1. Antibodies used in immune cell characterization by flow cytometry. Supplementary Table S2. PK parameters of ALT-803 administered to cynomolgus monkeys. Supplementary Table S3. Representative clinical characteristics of cynomolgus monkeys following 4 weekly doses of ALT-803 administration (study day 26). Supplementary Table S4. Incidence of major histopathologic findings in cynomolgus monkeys following 4 weekly doses of ALT-803 administration (study day 26). Supplementary Figure 1. Comparative binding of ALT-803 to IL-15 receptors on mouse, cynomolgus monkey, and human immune cells.
Supplementary Table S2 from Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Authors: Sweis Randy F. , Spranger Stefani , Bao Riyue , Paner Gladell P. , Stadler Walter M. , Steinberg Gary , Gajewski Thomas F.
Published: April 2023

Mutations exclusive to non-T cell-inflamed bladder cancers
Supplementary Figure 5 from The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor
Authors: Swierczak Agnieszka , Cook Andrew D. , Lenzo Jason C. , Restall Christina M. , Doherty Judy P. , Anderson Robin L. , Hamilton John A.
Published: April 2023

PDF file - 121K, Supplementary Figure 5: 4T1.2 and EMT6.5 tumor cells do not express CSF-1R.
Supplementary Figure S1 from Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Authors: Frazao Alexandra , Colombo Marina , Fourmentraux-Neves Emmanuelle , Messaoudene Meriem , Rusakiewicz Sylvie , Zitvogel Laurence , Vivier Eric , Vély Frédéric , Faure Florence , Dréno Brigitte , Benlalam Houssem , Bouquet Fanny , Savina Ariel , Pasmant Eric , Toubert Antoine , Avril Marie-Françoise , Caignard Anne
Published: April 2023

ERK expression of melanoma cell lines under Vemurafenib treatment.
Supplemental Table 3 from Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Authors: Frazao Alexandra , Colombo Marina , Fourmentraux-Neves Emmanuelle , Messaoudene Meriem , Rusakiewicz Sylvie , Zitvogel Laurence , Vivier Eric , Vély Frédéric , Faure Florence , Dréno Brigitte , Benlalam Houssem , Bouquet Fanny , Savina Ariel , Pasmant Eric , Toubert Antoine , Avril Marie-Françoise , Caignard Anne
Published: April 2023

Mutational profile of the BRAF non mutated melanoma cell lines.
Supplementary Table 1 from Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication
Authors: Arina Ainhoa , Karrison Theodore , Galka Eva , Schreiber Karin , Weichselbaum Ralph R. , Schreiber Hans
Published: April 2023

Cytokine production by 2C CD8+ T cells from mice treated or not with allogeneic CD4+ T cells
Supplementary Figure 3 from Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy
Authors: Campa Michael J. , Gottlin Elizabeth B. , Bushey Ryan T. , Patz Edward F.
Published: April 2023

Complement-dependent cytotoxicity of A549 lung cancer cells by the alternative pathway.
Supplementary Figures 1 - 4 from Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates
Authors: Avogadri Francesca , Zappasodi Roberta , Yang Arvin , Budhu Sadna , Malandro Nicole , Hirschhorn-Cymerman Daniel , Tiwari Shakuntala , Maughan Maureen F. , Olmsted Robert , Wolchok Jedd D. , Merghoub Taha
Published: April 2023

PDF file - 428K, Supplementary Figure S1. Depigmentation after combination therapy. Supplementary Figure S2. Tumor immune infiltrate after immunomodulation. Supplementary Figure S3. PD-1 expression on T cell subsets. Supplementary Figure S4. Effect of anti-CTLA4 on TILs.
Supplemental Figures 1 through 6 from Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Authors: Awad Mark M. , Jones Robert E. , Liu Hongye , Lizotte Patrick H. , Ivanova Elena V. , Kulkarni Meghana , Herter-Sprie Grit S. , Liao Xiaoyun , Santos Abigail A. , Bittinger Mark A. , Keogh Lauren , Koyama Shohei , Almonte Christina , English Jessie M. , Barlow Julianne , Richards William G. , Barbie David A. , Bass Adam J. , Rodig Scott J. , Hodi F. Stephen , Wucherpfennig Kai W. , Jänne Pasi A. , Sholl Lynette M. , Hammerman Peter S. , Wong Kwok-Kin , Bueno Raphael
Published: April 2023

Supplemental Figure 1. Difference in CD3+ immune cell infiltrates by histologic subtype of mesothelioma. Supplemental Figure 2. Comparison of immune cell infiltrates among patients who received or did not receive neoadjuvant chemotherapy prior to surgical resection of their tumor. Supplemental Figure 3. Quantification of monocyte subtypes in tumor samples. Supplemental Figure 4. Comparison of immune cell infiltrates by mutational subtype in mesothelioma samples. Supplemental Figure 5. Statistical analysis of t-SNE maps from Figure 6. Supplemental Figure 6. Kaplan-Meier overall survival analysis for patients according to histologic subtype, PD-L1 immunohistochemical status, and CD3 infiltration as assessed by either flow cytometry or immunohistochemistry.
Supplementary Figure 5 from Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Authors: Jeanbart Laura , Ballester Marie , de Titta Alexandre , Corthésy Patricia , Romero Pedro , Hubbell Jeffrey A. , Swartz Melody A.
Published: April 2023

PDF file - 42K, CD4+ T cells are more polyfunctional upon ex vivo restimulation when NP-OVA + NP-CpG is targeted to the tdLN.
Supplemental Figure 2 from Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
Authors: Curran Shane A. , Shyer Justin A. , St. Angelo Erin T. , Talbot Lillian R. , Sharma Sneh , Chung David J. , Heller Glenn , Hsu Katharine C. , Betts Brian C. , Young James W.
Published: April 2023

Inhibition of JAK1/2 with ruxolitinib reduces NK cell numbers and function among treated patients with myeloproliferative neoplasm (MPN).
Figure S2 from Tumor-Associated Macrophages Promote Epigenetic Silencing of Gelsolin through DNA Methyltransferase 1 in Gastric Cancer Cells
Authors: Wang Hao-Chen , Chen Chin-Wang , Yang Chia-Lung , Tsai I-Min , Hou Ya-Chin , Chen Chang-Jung , Shan Yan-Shen
Published: April 2023

Supplementary Figure S2. U937 cells are differentiated toward M2 type macrophages after coculture with gastric cancer cells. A, the schema shows the simplified in vitro coculture system of gastric cancer cells and tumor-associated macrophages. U937 cells were seeded into the lower wells, which were separated by a porous membrane in the upper transwells where gastric cancer cells were grown. B, cell lysates of U937 cells cocultured with or without gastric cancer cells were harvested for CD204 detection using Western blotting. C, changes of M1 and M2 cytokine transcription in U937 cells cocultured with or without gastric cancer cells were measured by qPCR. M1 cytokine: IL-1ÃŽÂ²; M2 cytokine: IL-10 and CCL2. *P < 0.05; ** P < 0.01 versus U937 monoculture, two-way ANOVA.
Supplemental Methods from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Authors: Moskalenko Marina , Pan Michael , Fu Yichun , de Moll Ellen H. , Hashimoto Daigo , Mortha Arthur , Leboeuf Marylene , Jayaraman Padmini , Bernardo Sebastian , Sikora Andrew G. , Wolchok Jedd , Bhardwaj Nina , Merad Miriam , Saenger Yvonne
Published: April 2023

Supplemental Methods
Supplemental Figure S5 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Authors: Moskalenko Marina , Pan Michael , Fu Yichun , de Moll Ellen H. , Hashimoto Daigo , Mortha Arthur , Leboeuf Marylene , Jayaraman Padmini , Bernardo Sebastian , Sikora Andrew G. , Wolchok Jedd , Bhardwaj Nina , Merad Miriam , Saenger Yvonne
Published: April 2023

Therapy with αTRP1+CY can activate T cells against melanoma.
Supplemental Figure S4 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Authors: Moskalenko Marina , Pan Michael , Fu Yichun , de Moll Ellen H. , Hashimoto Daigo , Mortha Arthur , Leboeuf Marylene , Jayaraman Padmini , Bernardo Sebastian , Sikora Andrew G. , Wolchok Jedd , Bhardwaj Nina , Merad Miriam , Saenger Yvonne
Published: April 2023

Absence of CD90+ populations in F4/80+ CD11b+ macrophages.
Supplemental Figure S3 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Authors: Moskalenko Marina , Pan Michael , Fu Yichun , de Moll Ellen H. , Hashimoto Daigo , Mortha Arthur , Leboeuf Marylene , Jayaraman Padmini , Bernardo Sebastian , Sikora Andrew G. , Wolchok Jedd , Bhardwaj Nina , Merad Miriam , Saenger Yvonne
Published: April 2023

Gating strategy to identify macrophage and MDSC populations.
Supplemental Figure Legends from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Authors: Moskalenko Marina , Pan Michael , Fu Yichun , de Moll Ellen H. , Hashimoto Daigo , Mortha Arthur , Leboeuf Marylene , Jayaraman Padmini , Bernardo Sebastian , Sikora Andrew G. , Wolchok Jedd , Bhardwaj Nina , Merad Miriam , Saenger Yvonne
Published: April 2023

Supplemental Figure Legends
Supplementary Figures 1 through 4 from Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Authors: Nathanson Tavi , Ahuja Arun , Rubinsteyn Alexander , Aksoy Bulent Arman , Hellmann Matthew D. , Miao Diana , Van Allen Eliezer , Merghoub Taha , Wolchok Jedd D. , Snyder Alexandra , Hammerbacher Jeff
Published: April 2023

1. Mutation burden and survival using updated mutation calling system. 2. Similarity scores between samples and viral or non-viral epitopes. 3. Deconvolution of immune infiltrates. 4. Gene set enrichment analysis.
Supplemental Figure 1 Legend from Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
Authors: Zdanov Stephanie , Mandapathil Magis , Abu Eid Rasha , Adamson-Fadeyi Saudat , Wilson Willie , Qian Jiahua , Carnie Andrea , Tarasova Nadya , Mkrtichyan Mikayel , Berzofsky Jay A. , Whiteside Theresa L. , Khleif Samir N.
Published: April 2023

Supplemental Figure 1 Legend
Supplementary Figures from FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors
Authors: Cremasco Viviana , Astarita Jillian L. , Grauel Angelo L. , Keerthivasan Shilpa , MacIsaac Kenzie , Woodruff Matthew C. , Wu Michael , Spel Lotte , Santoro Stephen , Amoozgar Zohreh , Laszewski Tyler , Migoni Sara Cruz , Knoblich Konstantin , Fletcher Anne L. , LaFleur Martin , Wucherpfennig Kai W. , Pure Ellen , Dranoff Glenn , Carroll Michael C. , Turley Shannon J.
Published: April 2023

Supplementary Figures 1-8
Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Authors: Josefsson Sarah E. , Beiske Klaus , Blaker Yngvild N. , Førsund Mette S. , Holte Harald , Østenstad Bjørn , Kimby Eva , Köksal Hakan , Wälchli Sébastien , Bai Baoyan , Smeland Erlend B. , Levy Ronald , Kolstad Arne , Huse Kanutte , Myklebust June H.
Published: April 2023

Supplementary figures S1-S8.
Supplemental figure 1 from The Protease-Dependent Mesenchymal Migration of Tumor-Associated Macrophages as a Target in Cancer Immunotherapy
Authors: Gui Philippe , Ben-Neji Myriam , Belozertseva Ekaterina , Dalenc Florence , Franchet Camille , Gilhodes Julia , Labrousse Arnaud , Bellard Elisabeth , Golzio Muriel , Poincloux Renaud , Maridonneau-Parini Isabelle , Le Cabec Véronique
Published: April 2023

Supplemental figure 1
Figure S2 from Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites
Authors: Morris Zachary S. , Guy Emily I. , Werner Lauryn R. , Carlson Peter M. , Heinze Clinton M. , Kler Jasdeep S. , Busche Sara M. , Jaquish Abigail A. , Sriramaneni Raghava N. , Carmichael Lakeesha L. , Loibner Hans , Gillies Stephen D. , Korman Alan J. , Erbe Amy K. , Hank Jacquelyn A. , Rakhmilevich Alexander L. , Harari Paul M. , Sondel Paul M.
Published: April 2023

Cooperative effect of RT and IT-hu14.18-IL2 is observed in mice bearing a single syngeneic Panc02-GD2+ tumor.
Supplementary Figure 4 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Authors: Mirlekar Bhalchandra , Michaud Daniel , Searcy Ryan , Greene Kevin , Pylayeva-Gupta Yuliya
Published: April 2023

This Figure demonstrates examples of p35+ and Ebi3+ B cells and T cells in primary human PDAC tumors, as well as gives examples of CD8 T cell infltrated versus depleted regions in tumors
Supplementary Figure 3 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Authors: Mirlekar Bhalchandra , Michaud Daniel , Searcy Ryan , Greene Kevin , Pylayeva-Gupta Yuliya
Published: April 2023

This figure demonstrates that deletion of IL12 subunit p40 does not activate anti-tumor immune response